Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists
Clinicians may consider a treatment switch to faricimab in nAMD and DMO patients who have suboptimal disease control or insufficient durability of response on initial anti-VEGF therapy.
Authors
- Clare Bailey (ORCID: https://orcid.org/0000-0003-2141-4512)
- Louise Downey (ORCID: https://orcid.org/0000-0001-5944-3437)
- Samer Elsherbiny
- Sobha Sivaprasad (ORCID: https://orcid.org/0000-0001-8952-0659)
- Antony Parker
- Andrew Lotery (ORCID: https://orcid.org/0000-0001-5541-4305)
- Ramandeep Chhabra
- Sarah‐Lucie Watson
- Soma Chakrabarti
- Giuliana Silvestri (ORCID: https://orcid.org/0000-0001-5662-5374)
- Gwyn Samuel Williams (ORCID: https://orcid.org/0009-0000-1912-2903)
- Saima Khokhar
- Jignesh Patel
Institutions
- Belfast Health and Social Care Trust (GB)
- Swansea Bay University Health Board (GB)
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University of Hull (GB)
- Hull University Teaching Hospitals NHS Trust (GB)
- NHS Greater Glasgow and Clyde (GB)
- Singleton Hospital (GB)
- University Hospitals Bristol NHS Foundation Trust (GB)
- Royal Berkshire NHS Foundation Trust (GB)
- Manchester Royal Eye Hospital (GB)
- University Hospital Southampton NHS Foundation Trust (GB)
- Manchester University NHS Foundation Trust (GB)
- Roche (United Kingdom) (GB)
- Colchester Hospital (GB)
- South Warwickshire NHS Foundation Trust (GB)
- Moorfields Eye Hospital (GB)
- University of Southampton (GB)
- University Hospitals Bristol and Weston NHS Foundation Trust (GB)
- University College London (GB)
Publication Details
- Journal
- Eye
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1038/s41433-024-03223-w
- Citations
- 12
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.46
Funders
- Amgen
- Sanofi
- Biogen
- Alimera Sciences
- Apellis Pharmaceuticals
- Janssen Pharmaceuticals